WILMINGTON, Del.--(BUSINESS WIRE)--Results from a US comparative effectiveness study of two maintenance treatment options for patients with a history of chronic obstructive pulmonary disease (COPD) ...
LONDON, Oct 29 (Reuters) - AstraZeneca Plc's asthma drug Symbicort can also improve lung function in patients with "smoker's lung", or chronic obstructive pulmonary disease (COPD), results of two ...
The U.S. Food and Drug Administration on Tuesday approved the first generic Symbicort drug used to treat asthma and chronic obstructive pulmonary disease (COPD), which are two common pulmonary health ...
WASHINGTON, Feb 27 (Reuters) - U.S. health regulators have approved AstraZeneca Plc's asthma drug Symbicort to also treat patients with the lung disorder known as COPD, or chronic obstructive ...
Pittsburgh-based Highmark Health signed an outcomes-based contract with drugmaker AstraZeneca for its asthma and chronic obstructive pulmonary disease drug Symbicort. The contract will apply to ...
Viatris’ generic Breyna could reach a large number of patients. The generic could generate $150 million in annual revenue for the company. Viatris’ shares today sell at an attractive valuation. This ...
In the courtroom fracas over the patents on AstraZeneca’s multibillion-dollar inhaler Symbicort, Viatris and Kindeva Drug Delivery have toppled yet another intellectual property pillar. Still, ...
Last December, Viatris (NASDAQ: VTRS) and Kindeva Drug Delivery lost in court against AstraZeneca (NASDAQ: AZN) over a patent dispute regarding one of the latter's patents for its asthma and chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results